Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28704 | 0.93 | HRH3 (0.52) | HPGDSHRH3MAPTALDH1A1SIRT6 | |
| SCHEMBL27817 | 0.87 | HPGDS (0.51) | HPGDSHRH3MAPTALDH1A1SIRT6 | |
| SCHEMBL27588 | 0.82 | HPGDS (0.54) | HPGDSMAPTALDH1A1MAPK1MEN1 | |
| SCHEMBL6730754 | 0.77 | MAPT (0.50) | HRH3MAPTALDH1A1MAPK1SIRT6 | |
| SCHEMBL19221745 | 0.77 | MAPT (0.53) | HRH3MAPTALDH1A1MAPK1SIRT6 | |
| SCHEMBL19221744 | 0.77 | MAPT (0.53) | HRH3MAPTALDH1A1MAPK1SIRT6 | |
| SCHEMBL28057 | 0.75 | HPGDS (0.52) | HPGDSHRH3MAPTALDH1A1SIRT6 | |
| SCHEMBL29020 | 0.75 | HPGDS (0.52) | HPGDSHRH3MAPTALDH1A1MAPK1 | |
| SCHEMBL27513 | 0.73 | HPGDS (0.52) | HPGDSHRH3MAPTALDH1A1SIRT6 | |
| SCHEMBL27718 | 0.72 | KMT2A (0.56) | HPGDSHRH3MAPTALDH1A1SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407466-B1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9062035-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8865714-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| CN-102341385-B | Piperazine compound capable of inhibiting prostaglandin d synthase | TAIHO PHARMACEUTICAL CO LTD | 2014-01-15 | — | — | CN | disclosed |
| EP-2407466-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGDR, PTGS1, PTGDR2 | HPGDS 9/4885HRH3 420/4885MAPT 4854/4885 |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGS1, PTGDR, PTGIS | HPGDS 10/4885HRH3 410/4885MAPT 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.